Peter Alff

Jazz Pharmaceuticals (EUSA Pharma USA), Inc. develops and markets biopharmaceutical products. The company was founded on November 7, 1980 and is headquartered in Princeton, NJ.

Part of KPMG International Cooperative, KPMG, Inc. provides audit and accounting services. The company is based in Vancouver, Canada. The CEO of the Canadian company is Walter R. Pela.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Learning Ally, Inc. provides educational support services. It produces & distributes tapes and CD-ROMs of textbooks for students as well as recordings of reference and professional materials to individuals with print disabilities such as blindness, visual impairments and dyslexia. The company was founded by Anne T. MacDonald in 1948 and is headquartered in Princeton, NJ.

Foundation Venture Capital Group LLC (Foundation Venture) is a venture capital firm headquartered in Princeton, New Jersey. Founded in 2006, the firm is the equity investment arm of New Jersey Health Foundation Inc.

Durin Technologies, Inc. engages in the development of blood tests to diagnose and monitor the progress of neurodegenerative diseases. The company was founded Robert G. Nagele in 2010 and is headquartered in Mullica Hill, NJ.

Celvive, Inc. engages in the development of technology for the isolation and use of autologous cellular therapy for regenerative medicine applications. It specializes in using a closed bag system to isolate specific adult stem cells from the patients' own bone marrow. The company was founded by Hatem E. Sabaawy in 2011 and is headquartered in New Brunswick, NJ.

NovoPedics, Inc. develops implantable medical devices that restore mobility to patients suffering from severe meniscus knee injuries. It provides a way to replace damaged meniscus tissue with a patented fiber-reinforced design similar to the native meniscus and can be attached to both soft tissue and bone, allowing it to be used in total meniscus replacement surgery. The company was founded by Charles J. Gatt Jr. and Michael G. Dunn in 2013 and is headquartered in New Brunswick, NJ.

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.

Kairos Venture Investments LLC (Kairos Venture) is a venture capital firm founded in 2015 by Jim Demetriades. The firm is headquartered in Beverly Hills, California.

Axial Therapeutics, Inc. provides biopharmaceuticals. It is harnessing the link between the human get microbiome and the central nervous system to develop a new class of biotherapeutics to improve the quality of life for people with neurological diseases and disorders. The company was founded by Sarkis Mazmanian and David H. Donabedian and is headquartered in Boston, MA.

1200 Pharma LLC engages in the provision of pre-clinical drug discovery and clinical approval timelines. The company is headquartered in Pasadena, CA.

Pinpoint Therapeutics, Inc. provides cancer treatment. The firm specializes in developing novel treatments for cancer. The company was founded by Jeffrey Winkler and Ravi Amaravadi in 2018 and is headquartered in Philadelphia, PA.

Leukovet develops peptide-based cancer therapeutics for the treatment of canine lymphoma, leukemia, and other immunological diseases. The company is based in New York, NY. The company was founded in 2019. The CEO is Sonia Gulati.

NemaGen Discoveries, Inc. is a biotech company located in Princeton, NJ. The company focuses on developing therapies for patients with allergic inflammation and mast cell-related diseases. NemaGen's unique approach to drug development involves investigating the body's natural ability to prevent unwanted inflammation following parasitic infections. Recently, NemaGen announced its participation in the NIH I-Corps program to better understand stakeholders' needs and validate the value of its therapies. The company was founded by Mark Siracusa and has been led by CEO Nicholas Shubin since 2022.